Osteoarthritis

phys.therapy.knee2_.jpg

Physical Therapy Underprescribed

MedPage Today

Just one patient in six was referred for physical therapy (PT) within 15 days of being treated for knee pain at one major U.S. health system, researchers found, despite nearly universal consensus that PT should be recommended in most cases.

Read Article
guidelines.jpg (keep)

Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer

EurekAlert!

An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for estrogen-responsive breast cancer, providing practical guidance for both osteoporosis specialists

Read Article
Chondrocalcinosis Increases Osteoarthritis Risk Analysis of data from two large, prospective cohort studies show that knee chondrocalcinosis was associated with an increased risk of incident knee osteoarthritis. https://t.co/Jd1Wb9lWpT https://t.co/QwXn2ehNie

Links:

Dr. John Cush @RheumNow( View Tweet )
Chondrocalcinosis

Chondrocalcinosis Increases Osteoarthritis Risk

Jack Cush, MD

Analysis of data from two large, prospective cohort studies show that knee chondrocalcinosis was associated with an increased risk of incident knee osteoarthritis.

Read Article
RheumNow Podcast square

A New RA Approval (8.1.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

Read Article
Osteoporosis Drug May Lower Osteoarthritis Risk A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. https://t.co/fWWw2t2jzR
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

CKD & Osteoporosis Rx Revisited (7.25.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.

Read Article
MRI.kneepain.jpg

Osteoporosis Drug May Lower Osteoarthritis Risk

Jack Cush, MD

A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis.

Read Article
Osteoarthritis (OA) degenerative or inflammatory? 296 pts w/ Knee OA (age 63 yrs, 2/3 had poor oral hygien, K&L grade 2, pain >40). Periodontitis in 62.5% & signif assoc w/ Xray K&L grade 4 (OR 5.39), poor oral hygiene (OR 34), dental visits (OR 8.54), brushing time (OR 21.9) https://t.co/xXIr2qxtt4
Dr. John Cush @RheumNow( View Tweet )
muscle%20aches.jpg

Americans choose short term relief for neck and back pain

EurekAlert!

New survey data from the Orlando Health Spine Center reveals a significant difference among Americans on how to manage neck and back pain. Respondents were split between relying on rest and reduced activity (44%), turning to over-the-counter pain

Read Article
human figures on blue circle

1 in 5 Patients are Unaware of their Arthritis Diagnosis

Jack Cush, MD

Current CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA.  Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million).

This most recent analysis of the prevalence and distribution of arthritis subtypes

Read Article
Genicular nerve block (GNB) is effective intervention for Knee OA. Metanalysis of 6 RCTs & 420 KOA pts. GNB significantly reduced pain & improved function (p<0.003), w/ significant relief as early as 2wks and function by 12 weeks. https://t.co/wC2dPvVR7x https://t.co/HCFSXBfVGM

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Hmmm Really? (7.11.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?

Read Article
Diffuse idiopathic skeletal hyperostosis (DISH)is a structural cause of dysphagia due to anterior cervical osteophytes. Retrospective study 208 dysphagia pts w/ head/neck CT. DISH was Dx in 39%; predicted by low serum albumin, COPD, & chronic pain https://t.co/zrn4dnCtLc https://t.co/svE6khmUEm

Links:

Dr. John Cush @RheumNow( View Tweet )
Genicular nerve block (GNB) is effective intervention for Knee OA. Metanalysis of 6 RCTs & 420 KOA pts. GNB significantly reduced pain & improved function (p<0.003), w/ significant relief as early as 2wks and function by 12 weeks. https://t.co/NMtiQPICpw https://t.co/gVJ0TyuY01

Links:

Dr. John Cush @RheumNow( View Tweet )
Weed, THC

ICYMI: ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain

Jack Cush, MD

The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.

Read Article
RheumNow Podcast square

PCR: Prevalence, Cost, & Risk (6.27.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Read Article
Global burden of dz study - UN statistics show post-Menopausal women (PMW) are 20% of all women in 2021 (vs 13.7% 1990). From 1990 to 2021, the prevalence of MSK Dz in PMW significantly risen, especially for RA, OA, and gout. https://t.co/HdkopkxLdv https://t.co/wsGhg0P1tL

Links:

Dr. John Cush @RheumNow( View Tweet )
Knee.pain_.ice_.injury_0.jpg

Simple Measures are Effective in Knee Osteoarthritis

EurekAlert!

Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of the First People’s Hospital of Neijiang, China.

Knee

Read Article
Reviewing Three Osteoarthritis Studies Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR

Links:

Dr. John Cush @RheumNow( View Tweet )
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/YDuUg44ebu
Dr. John Cush @RheumNow( View Tweet )
Presenteeism and absenteeism in RA aren’t just about joints. In this UK study, comorbid anxiety, depression, and OA drove lost productivity. Treating RA is not enough —holistic management matters. POS0403 @RheumNow #EULAR2025

Jiha Lee @JihaRheum( View Tweet )

The relation between RA, comorbidities and presenteism NRAS survey 891 RA pts 75% had at least one comorbidity Absenteeism more likely if One OR = 1.68 or Two OR = 2.26 comorbid conditions In particular Anxiety OR = 2.39 Depression OR = 1.75 Osteoarthritis OR = 1.85 Back

Aurelie Najm @AurelieRheumo( View Tweet )

What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory? Rx Retro study 388 patients RA 18% at least one sign CPPD ns diff between seeonegative and seropositive pts RA+CPPD group was -older -higher comorbidity score -more likely to be https://t.co/DaW5DZoDzF

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Targets for OA pain pharmacotherapies some by the wayside: - NGF - TrkA but some very much in play and exciting: - neurotrophin-3 - TRPV1 - Nav1.7, 1.8 Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo

Links:

David Liew @drdavidliew( View Tweet )

Recent Blogs

Best of 2023: PMR: glad or bad tidings?

Sarah Mackie, MRCP, PhD
Smile feedback opinion yes no good back opinion
Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on. Read Post

PMR: glad or bad tidings?

Sarah Mackie, MRCP, PhD
Smile feedback opinion yes no good back opinion
Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on. Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×